Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
Read original at benzingaStocks · News reference
8-K filing — Cartesian Therapeutics, Inc. (RNAC)
Filed: 2026-08-06 AccNo: 0001453687-26-000100 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 6, 2026, 11:03 AM
- Checked
- Aug 6, 2026, 11:03 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $(0.86) by 153.49 percent. This is a 8 percent decrease over earnings of $0.50 per share
Read original at benzingaNew Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthenia gravis trial planned for 2026.
Read original at benzinga